We've had Eyes On some of the recent deals, results, and investor actions. Check out the happenings at Sanofi/Opella, Pfizer, Regeneron, and

This month, we've had Eyes on investment trends, strategic restructuring, and FDA decisions. Fall seems to be gearing up, and we can't wait

This week we've had Eyes how BioPharma are bolstering their Portfolios for long-term success. From licensing assets ...

The news this week was full of "Ups-n-Downs." We've noted a few here and know there were more surprises with clinical data results, M&A, and